<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4159">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04792567</url>
  </required_header>
  <id_info>
    <org_study_id>CBAF312ADE03</org_study_id>
    <secondary_id>2020-005752-38</secondary_id>
    <nct_id>NCT04792567</nct_id>
  </id_info>
  <brief_title>Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)</brief_title>
  <acronym>AMA-VACC</acronym>
  <official_title>An Open-label Multicenter Study to Assess Response to SARS-CoV-2 modRNA Vaccines in Participants With Secondary Progressive Multiple Sclerosis Treated With Mayzent (Siponimod)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand whether participants can mount an immune response&#xD;
      to SARS-CoV-2 modRNA vaccines administered either during continuous siponimod treatment or&#xD;
      during a treatment break.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a three cohort, multicenter, open-label, prospective study of 60 (optionally up to&#xD;
      90) multiple sclerosis (MS) patients currently treated with siponimod or a first-line disease&#xD;
      modifying therapy (DMT) or without MS treatment in clinical routine planning to undergo a&#xD;
      SARS-CoV-2 modRNA vaccination as part of clinical routine. The maximal duration of the study&#xD;
      for an individual patient is 14 months.&#xD;
&#xD;
        -  The first cohort in this study will be participants not interrupting their current&#xD;
           siponimod therapy for the purpose of a SARS-CoV-2 modRNA vaccination.&#xD;
&#xD;
        -  The second cohort will be participants interrupting their current siponimod therapy for&#xD;
           the purpose of a SARS-CoV-2 modRNA vaccination for approximately 2-3 months.&#xD;
&#xD;
        -  The third cohort will be participants receiving modRNA vaccine while on treatment with&#xD;
           the following first-line DMTs (dimethylfumarate, glatirameracetate, interferons,&#xD;
           teriflunomide) or no current treatment in clinical routine.&#xD;
&#xD;
      The study will investigate the development of functional anti-SARS-CoV-2 antibodies and&#xD;
      T-cell titers for six months after the participants' vaccination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 19, 2021</start_date>
  <completion_date type="Anticipated">April 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 17, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants achieving seroconversion after receiving a modRNA vaccine</measure>
    <time_frame>at 1 week after second dose of vaccine</time_frame>
    <description>Seroconversion is defined by detection of SARS-CoV-2 serum functional antibodies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 serum functional antibody levels over time</measure>
    <time_frame>at baseline, 1 week, 1 month and 6 months after second dose of vaccine</time_frame>
    <description>SARS-CoV-2 neutralizing antibodies measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-cell response to modRNA vaccines over time</measure>
    <time_frame>at baseline, 1 week, 1 month and 6 months after second dose of vaccine</time_frame>
    <description>SARS-CoV-2 specific T-cell levels measured at the central laboratory e.g. by enzyme-linked immunosorbent spot (ELIspot) assay from peripheral blood mononuclear cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent adverse events, serious adverse events and COVID-19 infections</measure>
    <time_frame>Up to 12 months after second dose of vaccine</time_frame>
    <description>Untoward medical occurrences (including abnormal laboratory tests, vital signs and other safety assessments) will be captured as adverse events and COVID-19 infections will be recorded</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Secondary Progressive Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Siponimod - continuous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous treatment with siponimod (oral, daily, dose depending on CYP2C9 genotype: 2mg or 1 mg) during SARS-CoV-2 mRNA vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Siponimod- interrupted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Siponimod (oral, daily, dose depending on CYP2C9 genotype: 2mg or 1 mg) with treatment interruption (for approx. 2-3 months) for the purpose of a SARS-CoV-2 mRNA vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Baseline DMTs or no treatment during SARS-CoV-2 mRNA vaccination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAF312</intervention_name>
    <description>taken orally once per day (dose depends on CYP2C9 genotype)</description>
    <arm_group_label>Siponimod - continuous</arm_group_label>
    <arm_group_label>Siponimod- interrupted</arm_group_label>
    <other_name>Siponimod</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baseline disease modifying therapies (DMTs)</intervention_name>
    <description>DMTs: Dimethylfumarate, glatirameracetate, interferon, teriflunomode according to respective SmPC</description>
    <arm_group_label>Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Secondary Progressive Multiple Sclerosis (SPMS) diagnosis or with Relapsing Remitting&#xD;
             Multiple Sclerosis (RRMS) at risk to develop SPMS (at the discretion of the treating&#xD;
             physician)&#xD;
&#xD;
          -  on stable MS treatment (Siponimod, dimethylfumarate, glatirameracetate, interferon,&#xD;
             teriflunomode or no current treatment)&#xD;
&#xD;
          -  no recent treatment changes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  prior or current COVID-19 disease&#xD;
&#xD;
          -  SARS-CoV-2 antibodies at screening Other protocol-defined inclusion/exclusion criteria&#xD;
             may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>April 3, 2021</last_update_submitted>
  <last_update_submitted_qc>April 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2 mRNA vaccine</keyword>
  <keyword>Siponimod</keyword>
  <keyword>Secondary Progressive Multiple Sclerosis</keyword>
  <keyword>SPMS</keyword>
  <keyword>adult</keyword>
  <keyword>MS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

